ROMA is at present a valuable analytic device for the preoperative separation of patients with a pelvic mass, uncovering an awesome affectability and explicitness. Further investigations are required, in any case, in a huge gathering of patients and with tests from various producers to decide the ideal cutoff focuses for the calculation. ROMA performs better than CA125 and HE4 in type II and propelled diseases. Ladies with ovarian malignancy manifestations and adnexal masses present basically to gynecologists, essential consideration doctors or general specialists. ROMA is a qualitative serum test that derives a numerical score from the results of CA-125 (the most widely accepted biomarker for ovarian cancer) and HE4 blood tests, plus menopausal status, to identify patients presenting with an adnexal mass as being at high or low likelihood for having malignancy
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Review Article: BioTechnology: An Indian Journal
Review Article: BioTechnology: An Indian Journal
Review Article: BioTechnology: An Indian Journal
Review Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal
Original Article: BioTechnology: An Indian Journal